Document is current
Any future updates will be listed below
-
Authors
Qie, Shuo http://orcid.org/0000-0002-3481-3582
Xiong, Haijuan
Liu, Yaqi
Yan, Chenhui
Wang, Yalei
Tian, Lifeng
Wang, Chenguang
Sang, Nianli http://orcid.org/0000-0003-3405-7788
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82373360)
Tianjin Municipal Education Commission (2022ZD065)
U.S. Department of Health & Human Services | NIH | Center for Information Technology (CA129494)
- License Information
-
More Information
Article History
Received: 27 January 2024
Revised: 27 July 2024
Accepted: 29 July 2024
First Online: 6 August 2024
Competing interests
: The authors declare no competing interests.
: The protocol was approved by the Laboratory Animal Ethics Committee at the Tianjin Medical University Cancer Institute & Hospital (TMUCIH) (#: AE-2022036). This study has complied with all relevant ethical regulations for animal experiments. Every effort was made to minimise the numbers and suffering of the included animals. Human HCC tissue microarray (TMA) was purchased from the Shanghai Outdo Biotechnology with an Internal Review Board approval (YB M-05-02). Twenty-three cases of HCC specimens were also collected from the Department of Pathology at the TMUCIH. The inpatient time was from January 1, 2018, to December 31, 2018. All patients provided informed consent and this study was conducted according to the guidelines of the Internal Review Board at the TMUCIH (bc2021308).
